Comerica Bank Sells 4,526 Shares of Humana Inc. $HUM

Key Points

• Comerica Bank trimmed its Humana stake by 23.9% in Q4, selling 4,526 shares and leaving 14,390 shares worth $3.686 million.
• Insider Sanjay K. Shetty bought 810 shares at $185.21 on Feb. 23, raising his holding to 11,657 shares (a 7.47% increase).
• Humana beat Q1 estimates and prompted several price-target upgrades, but analyst sentiment remains mixed with a consensus "Hold" (7 Buy, 15 Hold, 4 Sell) and an average target around $247.6.

Comerica Bank reduced its holdings in Humana Inc. (NYSE:HUM - Free Report) by 23.9% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,390 shares of the insurance provider's stock after selling 4,526 shares during the quarter. Comerica Bank's holdings in Humana were worth $3,686,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Sanctuary Advisors LLC increased its stake in Humana by 1.6% in the 4th quarter. Sanctuary Advisors LLC now owns 3,389 shares of the insurance provider's stock worth $868,000 after acquiring an additional 52 shares during the last quarter. Vanguard Group Inc. increased its stake in Humana by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider's stock worth $3,652,890,000 after acquiring an additional 106,030 shares during the last quarter. Coronation Fund Managers Ltd. bought a new position in Humana in the 4th quarter worth about $2,569,000. Concurrent Investment Advisors LLC bought a new position in Humana in the 4th quarter worth about $308,000. Finally, Generali Investments Management Co LLC increased its stake in Humana by 333.7% in the 4th quarter. Generali Investments Management Co LLC now owns 1,119 shares of the insurance provider's stock worth $287,000 after acquiring an additional 861 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Humana news, insider Sanjay K. Shetty acquired 810 shares of the company's stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the acquisition, the insider owned 11,657 shares in the company, valued at $2,158,992.97. This represents a 7.47% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.20% of the company's stock.

Humana Trading Up 0.1%

NYSE HUM opened at $233.87 on Monday. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $315.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a 50 day simple moving average of $188.41 and a two-hundred day simple moving average of $226.98. The stock has a market cap of $28.08 billion, a P/E ratio of 25.01, a price-to-earnings-growth ratio of 2.16 and a beta of 0.68.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping the consensus estimate of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The business had revenue of $39.65 billion during the quarter, compared to analysts' expectations of $39.37 billion. During the same quarter last year, the business posted $11.58 EPS. The business's revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. On average, analysts forecast that Humana Inc. will post 9.06 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 annualized dividend and a yield of 1.5%. Humana's dividend payout ratio (DPR) is 37.86%.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Multiple brokers lifted price targets sharply (Jefferies, Mizuho, Cantor, Evercore, Truist, Leerink, Deutsche Bank), signaling renewed upside expectations and analyst confidence after the quarter. Jefferies PT to $290 Mizuho PT to $290 Cantor PT to $264
• Positive Sentiment: Company aims for at least a 3% Medicare Advantage margin by 2028 while preparing 2027 bids and integrating MaxHealth — a clear operational target that can support future margin recovery. MA margin target article
• Positive Sentiment: Deutsche Bank and other shops issued constructive commentary/forecasts supporting the stock after Q1, reinforcing buy-side interest. Deutsche Bank positive forecast
• Neutral Sentiment: Sector context: Humana was one of the top performers in April (≈+36%), nearly neck-and-neck with UnitedHealth; market rotation and sector momentum are lifting valuation comparisons. April returns piece
• Neutral Sentiment: Analyst consensus remains around "Hold"/"Market Perform" despite PT changes, so expectations are mixed rather than uniformly bullish. Consensus Hold report
• Negative Sentiment: Goldman raised its target to $195 but kept a sell rating — signaling conviction that the current price is rich versus fundamentals and creating downside pressure. Goldman sell rating
• Negative Sentiment: JPMorgan raised its target to $214 but kept a neutral rating — the PT implies downside from current levels and highlights lingering skepticism about sustainability of margins. JPMorgan PT to $214
• Negative Sentiment: Despite beating Q1 estimates, Humana warned Medicare payments may not keep pace with costs and reported a decline in Medicare Advantage Star ratings; those operational/framing issues are cited by multiple outlets as reasons the stock is under pressure. Q1 beat but Star ratings concern Bloomberg Law

Wall Street Analyst Weigh In

HUM has been the topic of a number of research analyst reports. Oppenheimer restated an "outperform" rating and issued a $260.00 target price on shares of Humana in a research note on Thursday. The Goldman Sachs Group upped their price objective on Humana from $158.00 to $195.00 and gave the stock a "sell" rating in a report on Thursday. Morgan Stanley set a $146.00 price objective on Humana in a report on Thursday, February 12th. Barclays upped their price objective on Humana from $176.00 to $180.00 and gave the stock an "equal weight" rating in a report on Thursday. Finally, Mizuho upped their price objective on Humana from $258.00 to $290.00 in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, Humana has an average rating of "Hold" and a consensus target price of $247.61.

Humana Company Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.